Key result
VWF-FVIII concentrate enhanced coagulation-dependent thrombus formation at low shear, but had minimal effects on platelet-dependent thrombus formation at high shear.
Why the study?
Does VWF-FVIII concentrate treatment improve thrombus formation under flow conditions in patients with type 3 von Willebrand disease?
Does VWF-FVIII concentrate treatment improve thrombus formation under flow conditions in patients with type 3 von Willebrand disease?
Conventional laboratory monitoring in VWD-3 patients may poorly predict bleeding due to insufficient restoration of platelet-dependent thrombus formation at high shear, despite improvements in low shear coagulation.
No takes yet. Share an insight, caveat, or question.
May inadequately restore high-shear platelet thrombus formation in type 3 VWD; hypothesis-generating for shear-specific monitoring.
Holmström et al. (2016) studied Type 3 von Willebrand disease (VWD-3) (n=20). VWF-FVIII concentrate (Haemate®) vs. Baseline (before injection) and healthy controls was evaluated on Thrombus formation under flow conditions measured by Total Thrombus Analysis System (T-TAS). VWF-FVIII concentrate enhanced coagulation-dependent thrombus formation at low shear, but had minimal effects on platelet-dependent thrombus formation at high shear.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: